Navigation Links
Helix BioPharma Approved for NYSE Amex Listing
Date:9/14/2010

AURORA, Ontario, Sept. 14 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: "HXBPF") today announced that it has been authorized to list its shares of common stock on the NYSE Amex stock exchange.  The Company expects that shares of its common stock will begin trading on the NYSE Amex on September 15, 2010, under the trading symbol "HBP." The Company will delist from the OTCQX once trading begins on the NYSE Amex.  The Company's listings on the Toronto and Frankfurt Stock Exchanges are unaffected by today's announcement.

"We are very pleased to reach this significant milestone as part of Helix's development and future growth initiatives," Dr. Donald H. Segal, chairman of the board and chief executive officer, stated. "We believe that listing on the NYSE Amex stock exchange will prove to benefit our existing shareholders by helping to increase Helix's visibility, liquidity and suitability for a broader group of investors."

"We are pleased to welcome Helix BioPharma Corp. to list its shares on NYSE Amex," said Scott Cutler, NYSE Euronext executive vice president. "We look forward to partnering with Helix BioPharma Corp. on NYSE Amex, the premier U.S. equities market for listing and trading small- and mid-cap growth companies, and to providing the highest levels of market quality to the company and its shareholders."

About Helix BioPharma Corp.Helix BioPharma Corp. is a biopharmaceutical company focused on cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies.  Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the Toronto and Frankfurt Stock Exchanges under the symbol "HBP" and on the OTCQX under the symbol "HXBPF."  For more information, please visit www.helixbiopharma.com. For further information contact:Robert Flamm, Ph.D.Russo Partners, LLCTel: (212) 845-4226Email: robert.flamm@russopartnersllc.com  www.russopartnersllc.comThis News Release contains certain forward-looking statements and information regarding Helix BioPharma Corp. ("Helix" or the "Company"), its proposed listing on the NYSE Amex stock exchange, expected benefits to shareholders from the listing, its planned de-listing from the OTCX, and its development activities, which statements and information can be identified by the use of forward looking terminology such as "expected," "will," "believe" and "future."  In making these statements, Helix has made certain assumptions, including that its common shares will be listed on NYSE Amex as expected.  Helix's actual results could differ materially from these forward-looking statements and information as a result of numerous risk factors, including without limitation, the risk that that Helix's common shares may not trade on the NYSE Amex by the expected date or at all, or may be delisted; the risk that the NYSE Amex listing will not provide any additional benefits to Helix or its shareholders; research & development risks, which may result in the Company's termination of either or both of its current product development programs; and Helix's continuing need for additional future capital to carry on its business.  Such risks and uncertainties, and others affecting the Company, are more fully described in the Company's latest MD&A, Form 20-F, and other reports filed with the Canadian Securities Regulatory Authorities and the U.S. S.E.C. from time to time at www.sedar.com and www.sec.gov/edgar.shtml respectively.  Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations change, except as required by law.


'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. RCSB PDB Teams with OpenHelix to Announce Free Tutorial and Training Materials
2. The Protein Structure Initiative announces free OpenHelix tutorial and training materials for the Structural Genomics Knowledgebase (SGKB)
3. Double Helix Consulting Enhances its Strategic Product Commercialization Services with Appointment of Michael Rizzo as Vice President
4. Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th
5. AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show
6. Helix BioPharma Closes Private Placement
7. Helix BioPharma Announces $13.5 Million Private Placement
8. Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
9. Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
10. New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix
11. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
(Date:6/23/2016)... June 23, 2016 On Wednesday, June ... 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% ... at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the ... Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. ... BIND ). Learn more about these stocks by ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
(Date:6/23/2016)... FRANCISCO , June 22, 2016  Amgen (NASDAQ: ... sponsorship of the QB3@953 life sciences incubator ... human health. The shared laboratory space at QB3@953 was ... overcome a key obstacle for many early stage organizations ... part of the sponsorship, Amgen launched two "Amgen Golden ...
Breaking Biology Technology:
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):